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Introduction 
N-methyl D-aspartate (NMDA) recep-
tors are glutamate receptors and responsible 
for controlling memory function and 
synaptic plasticity.
1
 Activation of these 
receptors requires binding with glutamate or 
aspartate. These receptors are present in the 
limbic system, hypothalamus, and fore-
brain.
2
 Binding of antibodies to these 
receptors lead to their removal from synaptic 
sites, thus leading to changes in functions.
3,4
 
Under-activity of these receptors is linked to 
development of psychotic symptoms as seen 
in schizophrenics and also in patients on 
PCP (angel dust) or ketamine.
3,5
   
NMDA-receptor antibody encephalitis 
was first seen in young women with 
underlying ovarian teratoma.
6
 Recent reports 
have shown that only 60% of patients have 
underlying tumor and the rest are idio-
pathic.
7,8
 The disease is known to effect 
young women predominantly (< 50 years) 
more than males,
2
 but cases involving 
children as young as eight months to two 
years also have been reported.
7,9
 Neoplasm 
is seen rarely in children and adolescents.
10
  
 
Case Report 
Liaison service was consulted regarding 
a 26-year-old female. She presented to the 
emergency room with acute onset of 
aphasia, auditory hallucinations, and 
agitation. She reported that the voices were 
instigating her to kill her own children. This 
patient was transferred from another hospital 
where she was admitted for difficulty in 
speaking and agitation.  
The patient had a history of anxiety and 
depression. She recently was started on 
clonazepam (1 mg every 8 hours) and 
hydroxyzine (25 mg TDS PRN) after her 
selective serotonin re-uptake inhibitors were 
discontinued due to anticipation of possible 
serotonin syndrome. 
The patient denied having a history of 
alcohol or substance abuse. In the ER, she 
was agitated and aggressive and had to be 
put on haloperidol (5 mg IV) and lorazepam 
(2 mg). Her vitals were normal and physical 
examination was unremarkable. The patient 
was not oriented. Her mental status was 
notable for incoherent speech, echolalia, and 
agitation. She was put in 4-point restrain. 
Routine lab investigation revealed a 
significant increase in blood glucose. 
Cerebrospinal fluid (CSF) analysis showed 
mild pleocytosis. Chest x-ray, electro-
cardiogram, and electro-encephalography 
were normal.  
The patient was transferred to neurology 
because of the altered mental status. She 
continued to have frequent episodes of 
agitation and confusion. Her speech was 
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largely incoherent and showed significant 
mood lability. The psychiatry consult team 
remained involved in this patient’s care, 
offering treatment for psychiatric symptoms, 
and helping in diagnostic formulation. 
No diagnostic clarity was achieved. She 
had a broad differential diagnosis including 
serotonin syndrome, schizophrenia, mood 
disorders, neuroleptic malignant syndrome, 
autoimmune disorders, and endocrine 
disorders. Causes, such as infection and 
inflammation, were considered. Throughout 
her stay, her metabolic panel was 
unremarkable, except blood glucose levels 
were elevated. Screening for autoimmune 
disorder also was negative. 
On hospital day 15, the patient was 
started on methylprednisolone with a 
presumptive diagnosis of NMDA enceph-
alitis. CSF analysis confirmed the presumed 
diagnosis (elevated IgG index). Plasma-
pheresis was included in her management. 
The following day, her agitation decreased 
and slowly her symptoms resolved. She 
responded to simple commands and formed 
simple sentences. 
 
Discussion 
Anti-NMDA receptor encephalitis is 
potentially lethal, but reversible if 
recognized early.
8
 It was considered as part 
of paraneoplastic syndrome,
4
 but recently a 
number of cases have been reported which 
are not associated with neoplasia.
4,8
 It 
should be suspected in young patients (espe-
cially females) who present with psychiatric 
symptoms, autonomic instability, hypo-
ventilation, and movement disorders.
8,11
 
Pathogenesis. Tumors (ovarian, testi-
cular, mediastinal) that express ectopic 
NMDA receptors or infections (Epstein-Barr 
virus, herpes simplex virus, mycoplasma, 
influenza A and B, chlamydia via molecular 
mimicry) activate specific antibody 
mediated immune responses, resulting in 
formation of memory B cells that can cross 
the blood brain barrier.
8
 Memory B cells 
produce NMDA receptor antibodies that 
bind to the receptors and internalize it 
resulting in loss of inhibition of excitatory 
pathway.
6-9
  
Clinically, the disease is divided into 
three stages.
9,12,13
 In the prodromal stage, 
patients experience fever, headache, fatigue, 
and lethargy. In the second stage, the patient 
develops behavioral abnormalities, impul-
sivity, confusion, stupor, and fluctuating 
consciousness. Patients often are presented 
to the psychiatrist or admitted with a 
diagnosis of schizophrenia, drug abuse, or 
acute psychosis. Autonomic instability is the 
third stage. The patient develops brady-
cardia, tachycardia, fluctuating blood 
pressure, heart block, and hypoventilation. 
If anti-NMDA receptor encephalitis is 
suspected, NMDA antibody titres in CSF 
and serum should be evaluated, followed by 
screening for tumor (whole body CT scan, 
chest x-ray) or infections (complete blood 
count with differential, urinalysis, CSF viral 
PCR, and cultures).
2,14
 In most cases, lumbar 
puncture shows elevated CSF IgG index 
with mild pleocytosis as compared to viral 
encephalitis.
15
 Brain magnetic resonance 
imaging may show mild cortical or sub-
cortical increased signal on fluid attenuated 
inversion recovery sequence.
14,15
 Anti-
NMDA receptor encephalitis is confirmed 
by screening NMDA antibody titers in 
serum and CSF. The titers of antibodies are 
higher in CSF than in serum indicating 
intrathecal synthesis.
11
 
Management. The goal of initial 
management should be resolution of psychi-
atric symptoms, plasmapheresis, plasma 
exchange, immunosuppression (steroids, 
immunoglobulins), and removal of tumor if 
present.
8,9,12
 However, there is lack of 
information on specific management of 
psychiatric symptoms. In case of poor 
clinical response or relapse, rituximab 
(monoclonal antibody that depletes B cell) 
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or cyclophosphamide can be tried. 
Psychotropic medications used to control 
behavioral symptoms include haloperidol, 
atypical antipsychotics (olanzapine, 
risperidone, ziprasidone), and benzo-
diazepines. 
Given the complex nature and 
presentation of this disorder, a multi-
disciplinary approach (psychiatry, neuro-
logy, and surgery) is required. There is slow 
but continuous improvement and the 
majority of patients make a good recovery.
8-
10
 Patients are at risk of relapse so long term 
therapy and surveillance is required.
12
 
 
Conclusion  
Anti-NMDAR encephalitis is a common 
cause of encephalitis. Its relative frequency 
is close to some common infectious 
etiologies for encephalitis like HSV-1 in 
young individuals.
6,11
 There has been an 
increase in reporting of anti-NMDAR 
encephalitis in recent years. Therefore, it is 
important to keep it high on the differential 
diagnosis. This will avoid unnecessary 
diagnostic and treatments cost and help in 
timely diagnosis and effective treatment.  
More research is required to clarify the exact 
pathogenesis and best treatment.  
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